This article is more than 5 years old. Information may no longer be current.
Highlights from ESC Congress: DAPA-HF, new guidelines, intervention updates and more
Click Here to Manage Email Alerts
Whether you attended the European Society of Cardiology Congress in person or followed from afar, Cardiology Today and Healio have you covered.
Our team provided live coverage of the annual meeting in Paris, with the most-popular articles listed below. Read more for updates on a diabetes drug that showed benefit in patients with HF, with and without diabetes;
Coverage from this meeting will continue. Visit Healio’s ESC Congress page for additional news, perspective from leaders in cardiology, video interviews and more.
DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes
In patients with HF, with and without diabetes, treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) reduced risk for worsening HF and CV death when added to standard therapy, according to anticipated results of the DAPA-HF trial. Read more
ISAR-REACT 5: Prasugrel superior to ticagrelor in patients with ACS, planned invasive evaluation
In patients with acute coronary syndromes, with or without ST-segment elevation, the rate of death, MI or stroke was significantly reduced at 1 year with prasugrel compared with ticagrelor, without an increase in major bleeding, according to a head-to-head comparison of both strategies. Read more
Updated ESC guidelines offer new recommendations on lipids, diabetes and more
The ESC released five new guidelines, which introduce fresh recommendations such as an LDL goal of less than 55 mg/dL in patients at very high risk for CVD and the use of SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes requiring CVD prevention. Read more
PARAGON-HF: Sacubitril/valsartan misses primary endpoint for HFpEF; may still provide insight into unmet need
Sacubitril/valsartan (Entresto, Novartis) did not reduce the rate of hospitalizations for CV-related death and HF in patients with HF with preserved ejection fraction, defined as at least 45%. Read more
Rivaroxaban monotherapy noninferior to combo therapy for AF, stable CAD
In the AFIRE trial, rivaroxaban (Xarelto, Janssen) monotherapy was noninferior to rivaroxaban plus an antiplatelet agent with respect to CV events and death from any cause, and was superior for major bleeding in patients with atrial fibrillation and stable CAD. Read more
Evolocumab shows benefit for high-risk ACS: EVOPACS
In the first randomized trial designed to assess a PCSK9 inhibitor in patients with ACS, the addition of evolocumab (Repatha, Amgen) to statin therapy was well tolerated and substantially reduced LDL levels, with a majority of patients within currently recommended target levels following treatment. Read more
MITRA-FR: No change in death, unplanned HF hospitalization at 2 years
In patients with HF with reduced ejection fraction and secondary mitral valve regurgitation, percutaneous mitral valve repair with MitraClip (Abbott) plus medical therapy offered no advantage over medical therapy alone for the outcomes of death and unplanned hospitalization for HF at 2 years. Read more
Twice-yearly inclisiran injection shows durable LDL improvement: ORION-11
Inclisiran (The Medicines Company), an investigational cholesterol-lowering therapy in the small-interfering RNA class, achieved durable and potential LDL reduction with twice-yearly injections, according to new data from the ORION-11 study. Read more
SYNTAXES: No mortality difference at 10 years with PCI or CABG
Ten-year follow-up data from the SYNTAXES trial highlight no significant difference in all-cause death among patients who underwent PCI using first-generation paclitaxel-eluting stents or CABG. Read more
Complete revascularization superior to culprit lesion-only PCI for STEMI, multivessel CAD: COMPLETE
Complete revascularization was superior to culprit lesion-only PCI for reducing risk for CV death or MI in patients with STEMI and multivessel CAD. Read more